Top of this page
Skip navigation, go straight to the content
UCB is a global biopharmaceutical company focused on creating value for people living with severe diseases in immunology and neurology.
We work with stakeholders to address the unmet needs of patients and caregivers, helping them to achieve their goals and to live the lives they want. UCB is on a journey to become the patient-preferred biopharma leader by delivering medicines and solutions that improve lives. Our commitment to value is a promise to bring together the talent, expertise, tools and scientific know-how required to serve patients in need.
UCBCares: Providing Dedicated Patient Support
Clinical studies at UCB: How are medicines made and tested?
![UCB acquires Engage Therapeutics: Staccato[®] Alprazolam - A potential solution for acute on-demand seizure management for people living with epilepsy](/_up/ucb_com_presscenter/images/presscenter_teaser_4.jpg?300)
Twitter Feed
-
We remain committed to providing innovative solutions around the world to address the unmet needs of women, especially those over 50, who face significant challenges caused by #osteoporosis. https://t.co/6QlwMxakyv
— UCB News (@ucb_news) 05.06.2020 -
UCB announced the acquisition of Engage Therapeutics, a company with genuine passion in epilepsy https://t.co/vSMLSEaBfK
— UCB News (@ucb_news) 05.06.2020 -
Women with chronic inflammatory diseases (CIDs), specifically those of childbearing age, can face unique challenges during their treatment journey. We remain committed to identifying and addressing these unmet needs. #EULAR2020 https://t.co/F7X94EFB2N
— UCB News (@ucb_news) 05.06.2020
Instagram Feed
At UCB, we take our responsibility
to the planet very seriously.
UCB Ventures, our strategic corporate venture fund established in 2017
